Pooled Dosing and Efficacy Analysis of the Sufentanil Sublingual Tablet 30 mcg Across Demographic Subgroups for the Management of Moderate-to-Severe Acute Pain
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 01, 2020
- Source ID
- 10.1016/j.jopan.2019.08.009
Entities
People
- David Leiman
- Jacob L. Hutchins
- Karen P. Didonato
- Pamela Pierce Palmer
- Zubaid Rafique
Organizations
- AcelRx Pharmaceuticals (United States)
- United States Army Medical Research and Development Command